Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China Requires One Divestiture for Pfizer-Wyeth Merger

publication date: Sep 30, 2009

The Anti-Monopoly Bureau of China’s Ministry of Commerce (MOFCOM) has given its okay to the merger between Pfizer and Wyeth. However, MOFCOM will require that Pfizer divest its swine mycoplasmal pneumonia vaccine business. Pfizer has been negotiating with the Anti-Monopoly Bureau on the ruling, implying that it will not be surprised by the ruling, even if it may not agree. More details...

Stock Symbols: (NYSE: PFE) (NYSE: WYE)



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital